Recent Findings from Department of Pharmacy Provides New Insights into B-Cell Lymphoma (Safety of Loncastuximab Tesirine-lpyl In Diffuse Large B-cell Lymphoma With Severe Hepatic Dysfunction).

Keywords: Seattle; State:Washington; United States; North and Central America; B-Cell Lymphoma; Cancer; Drugs and Therapies; Health and Medicine; Hematology; Immunologic Agents; Immunoproliferative Disorders; Large B-Cell Lymphoma; Loncastuximab Therapy; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Monoclonal Antibodies; Oncology; Pharmaceuticals EN Seattle State:Washington United States North and Central America B-Cell Lymphoma Cancer Drugs and Therapies Health and Medicine Hematology Immunologic Agents Immunoproliferative Disorders Large B-Cell Lymphoma Loncastuximab Therapy Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Monoclonal Antibodies Oncology Pharmaceuticals 1556 1556 1 06/19/23 20230620 NES 230620 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Oncology - B-Cell Lymphoma have been published. Keywords for this news article include: Seattle, Washington, United States, North and Central America, B-Cell Lymphoma, Cancer, Drugs and Therapies, Health and Medicine, Hematology, Immunologic Agents, Immunoproliferative Disorders, Large B-Cell Lymphoma, Loncastuximab Therapy, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Monoclonal Antibodies, Oncology, Pharmaceuticals, Department of Pharmacy. Seattle, State:Washington, United States, North and Central America, B-Cell Lymphoma, Cancer, Drugs and Therapies, Health and Medicine, Hematology, Immunologic Agents, Immunoproliferative Disorders, Loncastuximab Therapy, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Monoclonal Antibodies, Oncology, Pharmaceuticals, Large B-Cell Lymphoma. [Extracted from the article]